Monte Rosa Therapeutics近日披露了其候选药物Mrt-8102一期临床试验的积极中期结果。数据显示,该药物在高心血管疾病风险受试者中表现出显著的C反应蛋白降低效果,为后续临床开发提供了有力支持。
Monte Rosa Therapeutics近日披露了其候选药物Mrt-8102一期临床试验的积极中期结果。数据显示,该药物在高心血管疾病风险受试者中表现出显著的C反应蛋白降低效果,为后续临床开发提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.